Wound Management Technologies Receives Investment; Fully Pays Notes to Brookhaven Medical, Inc.; Mr. S. Oden Howell, Jr. Appointed to the Board of Directors

ADDISON, TX / ACCESSWIRE / June 18, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that it has fully paid short term loans due to Brookhaven Medical Inc. This was made possible by investments from existing shareholders.

The new $1.2 million investment was made as long term Senior Secured Promissory Notes which have a three year maturity date. The notes which have a conversion feature have no interest or principle due until the maturity date. Full details are filed in the corresponding Form 8-K.

In conjunction with the new investment, Mr. S. Oden “Denny” Howell, Jr. has been appointed to the Wound Management Board of Directors and Mr. John Feltman of Brookhaven Medical has resigned from the board. Mr. Howell is a long term investor in pharmaceutical and medical device companies, as well as a past director of a pharmaceutical company.

“We are extremely pleased that our investors continue to support Wound Management and our CellerateRX growth strategy and that Denny Howell has joined our Board,”  commented Robert Lutz, Jr., Wound Management CEO. “Denny brings a wealth of experience in emerging medical companies as well as other businesses to our board and we look forward to his expertise and involvement as we continue to build the CellerateRX market.”

“Replacing the Brookhaven short-term debt with a long term debt instrument allows us to keep focused on our CellerateRX growth strategy and to continue to invest in our regional sales management team and surgical sales channel,” continued Mr. Lutz.

About Wound Management Technologies

Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its Wound Care Innovations subsidiary’s unique, patented collagen product line, CellerateRX(R) which is FDA-cleared for all wound types except 3rd degree burns. The wound care product line is reimbursable under Medicare Part B and the surgical products are reimbursable as part of procedural billing. Wound Management has other advanced biotech products in development including a patented resorbable bone hemostat line that is in late stages of development. For more information visit www.wmgtech.com.

To download Wound Management Technologies’ investor relations app, which offers access to SEC documents, press releases, audio casts and more, please visit http://bit.ly/1zhNwnO to download on your iPhone and iPad or http://bit.ly/149PgWc for your Android mobile device.

Information about Forward-Looking Statements

The statements in the press release that relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contacts:

Investor Relations
972.218.0935
info@wmgtech.com

SOURCE: Wound Management Technologies, Inc.

ReleaseID: 429932